Cargando…

Ferroptosis in liver disease: new insights into disease mechanisms

Characterized by excessive iron accumulation and lipid peroxidation, ferroptosis is a novel form of iron-dependent cell death, which is morphologically, genetically, and biochemically distinct from other well-known cell death. In recent years, ferroptosis has been quickly gaining attention in the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jing, Wang, Yi, Jiang, Rongtao, Xue, Ran, Yin, Xuehong, Wu, Muchen, Meng, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492622/
https://www.ncbi.nlm.nih.gov/pubmed/34611144
http://dx.doi.org/10.1038/s41420-021-00660-4
_version_ 1784578953357295616
author Wu, Jing
Wang, Yi
Jiang, Rongtao
Xue, Ran
Yin, Xuehong
Wu, Muchen
Meng, Qinghua
author_facet Wu, Jing
Wang, Yi
Jiang, Rongtao
Xue, Ran
Yin, Xuehong
Wu, Muchen
Meng, Qinghua
author_sort Wu, Jing
collection PubMed
description Characterized by excessive iron accumulation and lipid peroxidation, ferroptosis is a novel form of iron-dependent cell death, which is morphologically, genetically, and biochemically distinct from other well-known cell death. In recent years, ferroptosis has been quickly gaining attention in the field of liver diseases, as the liver is predisposed to oxidative injury and generally, excessive iron accumulation is a primary characteristic of most major liver diseases. In the current review, we first delineate three cellular defense mechanisms against ferroptosis (GPx4 in the mitochondria and cytosol, FSP1 on plasma membrane, and DHODH in mitochondria), along with four canonical modulators of ferroptosis (system Xc(−), nuclear factor erythroid 2-related factor 2, p53, and GTP cyclohydrolase-1). Next, we review recent progress of ferroptosis studies delineating molecular mechanisms underlying the pathophysiology of several common liver diseases including ischemia/reperfusion-related injury (IRI), nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hemochromatosis (HH), drug-induced liver injury (DILI), and hepatocellular carcinoma (HCC). Furthermore, we also highlight both challenges and promises that emerged from recent studies that should be addressed and pursued in future investigations before ferroptosis regulation could be adopted as an effective therapeutic target in clinical practice.
format Online
Article
Text
id pubmed-8492622
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84926222021-10-07 Ferroptosis in liver disease: new insights into disease mechanisms Wu, Jing Wang, Yi Jiang, Rongtao Xue, Ran Yin, Xuehong Wu, Muchen Meng, Qinghua Cell Death Discov Review Article Characterized by excessive iron accumulation and lipid peroxidation, ferroptosis is a novel form of iron-dependent cell death, which is morphologically, genetically, and biochemically distinct from other well-known cell death. In recent years, ferroptosis has been quickly gaining attention in the field of liver diseases, as the liver is predisposed to oxidative injury and generally, excessive iron accumulation is a primary characteristic of most major liver diseases. In the current review, we first delineate three cellular defense mechanisms against ferroptosis (GPx4 in the mitochondria and cytosol, FSP1 on plasma membrane, and DHODH in mitochondria), along with four canonical modulators of ferroptosis (system Xc(−), nuclear factor erythroid 2-related factor 2, p53, and GTP cyclohydrolase-1). Next, we review recent progress of ferroptosis studies delineating molecular mechanisms underlying the pathophysiology of several common liver diseases including ischemia/reperfusion-related injury (IRI), nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hemochromatosis (HH), drug-induced liver injury (DILI), and hepatocellular carcinoma (HCC). Furthermore, we also highlight both challenges and promises that emerged from recent studies that should be addressed and pursued in future investigations before ferroptosis regulation could be adopted as an effective therapeutic target in clinical practice. Nature Publishing Group UK 2021-10-05 /pmc/articles/PMC8492622/ /pubmed/34611144 http://dx.doi.org/10.1038/s41420-021-00660-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Wu, Jing
Wang, Yi
Jiang, Rongtao
Xue, Ran
Yin, Xuehong
Wu, Muchen
Meng, Qinghua
Ferroptosis in liver disease: new insights into disease mechanisms
title Ferroptosis in liver disease: new insights into disease mechanisms
title_full Ferroptosis in liver disease: new insights into disease mechanisms
title_fullStr Ferroptosis in liver disease: new insights into disease mechanisms
title_full_unstemmed Ferroptosis in liver disease: new insights into disease mechanisms
title_short Ferroptosis in liver disease: new insights into disease mechanisms
title_sort ferroptosis in liver disease: new insights into disease mechanisms
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492622/
https://www.ncbi.nlm.nih.gov/pubmed/34611144
http://dx.doi.org/10.1038/s41420-021-00660-4
work_keys_str_mv AT wujing ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT wangyi ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT jiangrongtao ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT xueran ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT yinxuehong ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT wumuchen ferroptosisinliverdiseasenewinsightsintodiseasemechanisms
AT mengqinghua ferroptosisinliverdiseasenewinsightsintodiseasemechanisms